证券代码：300759 证券简称：康龙化成 康龙化成（北京）新药技术股份有限公司投资者关系活动记录表 编号：2023-02 | □特定对象调研 | □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 活动类别 | | | | □现场参观 | | | √其他 （电话会议） | | 参与单位名称及 | International, Inc.中国人保、华夏基金、银华基金、嘉实资产、广发基金、 | | | 华夏基金、建信养老、国寿养老、太平养老、平安养老、新华养老、中 | | | 国人寿、阳光资产、平安资产、富国基金、博时基金、鹏华基金、汇添 | | | 富基金、泰达宏利基金、天弘基金、海富通基金、中银基金、太平基金、 | | | 上投摩根基金、英大国际信托等 余家机构 余名参与人员 400 410 | | | 日 31 09:00-11:30 | | 地 点 | 公司会议室 | | 上市公司接待人 | | | 员姓名 | | | | 首席财务官、董事会秘书：李承宗先生 | | 投资者关系活动 | 年度报告 2022 进行分析解读。 2022 年度，公司实现营业收入超过 100 亿 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd.* 康龍化成（北京）新藥技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 截至2022年12月31日止年度全年業績公告 財務摘要及要點 截至12月31日止年度 2022年 2021年 變動 人民幣千元 人民幣千元 % 收益 10,266,288 7,443,770 37.9 毛利 3,749,276 2,672,044 40.3 母公司擁有人應佔利潤 1,374,604 1,661,029 (17.2) 母公司擁有人應佔非國際財務報告 準則經調整淨利潤 1,834,271 1,461,985 25.5 經營活動所得現金流量淨額 2,142,816 2,058,044 4.1 － 於報告期間，本集團錄得總收益約人民幣10,266.3百萬元，較截至2021年 12月31日止年度增加約人民幣2,822.5百萬元或37.9% ...

证券代码：300759 证券简称：康龙化成 公告编号：2023-022 康龙化成（北京）新药技术股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）定于 2023 年 4 月 21 日（星期五）15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度 业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动 平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总经理 Boliang Lou 先生、财务负 责人兼董事会秘书李承宗先生、独立非执行董事李丽华女士、东方证券承销保荐 有限公司保荐代表人郑睿先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 20 日（星期四）15:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入 问 ...

Revenue and Profitability - Total revenue for Q3 2022 reached CNY 2,768,208,563.01, an increase of 37.31% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 20.95% to CNY 375,674,760.35 for Q3 2022[4] - Operating revenue increased to ¥7,402,793,998.96, a year-on-year growth of 39.63% compared to ¥5,301,532,904.44[8] - Total revenue for the nine months ended September 30, 2022, was RMB 7,402,794 thousand, an increase from RMB 5,301,533 thousand in the same period of 2021, representing a growth of 32.5%[46] - Net profit for the current period is 944,178,254.54, down from 1,003,928,223.19 in the previous period, indicating a decrease of approximately 5.9%[35] - The company reported a profit attributable to equity holders of RMB 961,107 thousand for the nine months ended September 30, 2022, down from RMB 1,040,063 thousand in 2021, indicating a decline of 7.6%[51] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of CNY 1,395,070,031.14 for the year-to-date period, a decrease of 1.46% compared to the previous year[4] - Cash and cash equivalents decreased by 42.36% to ¥2,042,501,533.84 from ¥3,543,819,700.44, a reduction of ¥1,501,318,200[8] - Cash inflow from operating activities is 7,076,581,251.14, an increase from 5,410,437,911.75 in the previous period, reflecting a growth of approximately 30.8%[37] - Cash outflow from investment activities is 5,208,210,770.23, down from 7,505,559,923.92 in the previous period, indicating a reduction of approximately 30.5%[42] - Cash and cash equivalents decreased to RMB 1,780,290 thousand from RMB 3,526,577 thousand at the beginning of the year, indicating a decline of 49.5%[47] Assets and Liabilities - The total assets as of the end of Q3 2022 were CNY 19,706,904,963.16, reflecting a 7.17% increase from the end of the previous year[4] - Total liabilities increased to CNY 9,165,741,734.83 from CNY 8,093,817,609.58, marking a rise of 13.2%[26] - Total non-current assets increased to RMB 13,054,092 thousand as of September 30, 2022, up from RMB 9,745,622 thousand at the beginning of the year, marking a growth of 33.7%[47] - The company’s total assets less current liabilities amounted to RMB 16,060,504 thousand, an increase from RMB 15,407,128 thousand at the beginning of the year[47] Equity and Shareholder Information - The total equity attributable to shareholders was CNY 10,401,703,789.08, a 2.69% increase from the end of the previous year[4] - The total number of common shareholders at the end of the reporting period was 34,592[18] - The top ten shareholders collectively hold significant stakes, with HKSCC NOMINEES LIMITED owning 16.88% and Shenzhen Xinchongkang Investment Partnership holding 16.79%[19] Expenses and Cost Management - Total operating costs increased by 39.81% to ¥4,701,717,656.76 from ¥3,362,990,019.03, in line with revenue growth[14] - Sales expenses increased by 56.20% to ¥163,039,241.44 compared to ¥104,381,393.02 in the same period last year[15] - Management expenses rose by 73.19% to ¥1,036,265,811.81 from ¥598,348,091.85 year-on-year, primarily due to increased personnel costs and acquisitions[15] - R&D expenses grew by 61.55% to ¥177,468,493.98, up from ¥109,851,832.35, reflecting the company's commitment to enhancing R&D capabilities[15] Profit Margins and Earnings Per Share - The basic earnings per share for Q3 2022 was CNY 0.3171, down 20.71% year-on-year[4] - The net profit excluding non-recurring gains and losses increased by 8.79% to CNY 377,837,497.51 for Q3 2022[4] - Basic earnings per share for the current period is 0.8118, down from 0.8754 in the previous period, representing a decrease of approximately 7.3%[36] Government Support and Subsidies - The company received government subsidies amounting to CNY 11,466,691.04 during the reporting period[6]

Financial Performance - The total revenue for the six months ended June 30, 2022, was approximately RMB 4,634.6 million, an increase of about RMB 1,349.1 million or 41.1% compared to the same period in 2021[8]. - The gross profit for the same period was RMB 1,613.1 million, reflecting a growth of 35.6% from RMB 1,189.7 million in the previous year[8]. - The profit attributable to equity holders of the parent company was approximately RMB 585.4 million, up by 3.6% from RMB 564.8 million in the prior year[9]. - The adjusted net profit for the period was RMB 812.1 million, representing a 24.7% increase from RMB 651.4 million in the previous year[9]. - The net cash flow from operating activities was approximately RMB 858.8 million, a slight increase of 1.6% compared to RMB 845.1 million in the same period last year[9]. - Basic earnings per share were approximately RMB 0.4941, up 4.0% from approximately RMB 0.4751 for the six months ended June 30, 2021[22]. - The company reported a profit of RMB 1,191,068,000 for the six months ending June 30, 2022, compared to RMB 794,177,000 for the same period in 2021, representing a year-over-year increase of approximately 50%[84]. - The total comprehensive income for the period was RMB 547,136,000, compared to RMB 564,837,000 in the previous period, indicating a slight decline[86]. Revenue Breakdown - Revenue from North American clients accounted for 65.6%, while European clients contributed 13.6%, and Chinese clients contributed 17.7%[11]. - The laboratory services segment generated revenue of RMB 2,860.1 million, a 41.1% increase year-on-year, with a gross margin of 43.4%[12]. - CMC (small molecule CDMO) services achieved revenue of RMB 1,084.6 million, a year-on-year increase of 42.3%, with a gross margin of 32.9%, down 3.6 percentage points from the previous year[13]. - Clinical research services generated revenue of RMB 584.5 million, up 38.3% year-on-year, with a gross margin of 5.1%, down 9.0 percentage points from the previous year[14]. - The company’s large molecule and cell and gene therapy services reported revenue of RMB 95.5 million, a 33.2% increase year-on-year, but with a gross margin of -19.8% due to high operational costs[16]. Operational Highlights - The company introduced over 400 new clients in the first half of 2022, expanding its customer base significantly[11]. - The company operates in China, the United States, and the United Kingdom, employing over 17,000 staff[6]. - The company has over 800 ongoing clinical trial projects and collaborates with more than 600 hospitals and clinical trial centers across 140 cities in China[15]. - The company has established a comprehensive chemical technology platform that covers the entire process of small molecule drug research, development, and production, enhancing its competitive advantage in the pharmaceutical R&D service market[31]. - The company has strengthened its integrated service platform through international acquisitions, enhancing service capabilities and R&D efficiency, exemplified by the acquisition of a production base in Cramlington, UK[35]. Strategic Initiatives - The company aims to accelerate drug innovation and become a global leader in multi-therapy drug development services[10]. - The company is focused on enhancing its service platform's synergy through vertical and horizontal integration in drug development[10]. - The company has committed to the Science Based Targets initiative (SBTi) to align its carbon reduction goals with international climate agreements[12]. - The company aims to enhance its integrated drug development service platform, focusing on small molecule research while accelerating the development of large molecule and cell/gene therapy services[40]. - The company plans to expand its laboratory chemistry capabilities and strengthen its CDMO services in small molecules, with a strategic focus on technology investment and service content expansion[41]. Acquisitions and Investments - The company acquired 100% equity of Beijing Ankai Yibo Biotechnology Co., Ltd. to enhance its capabilities in drug safety evaluation and biological sciences[13]. - The acquisition of Aesica Pharmaceuticals Limited was completed in January 2022 for approximately GBP 55 million (about RMB 473.35 million), enhancing the company's CDMO service platform[26]. - Pharmaron Manufacturing Services (US) LLC acquired the Coventry API production facility in Rhode Island for approximately $31.5 million (RMB 210.6 million), completed on July 1, 2022[78]. - The company completed the acquisition of Pharmaron Manufacturing Services (UK) Ltd for a cash consideration of GBP 58,052,000 (approximately RMB 500,837,000) on January 7, 2022[154]. Market Outlook - The global pharmaceutical market's R&D and production investment was approximately $566.1 billion in 2021, projected to reach $726.1 billion by 2026, with a CAGR of 6.5%[37]. - The Chinese pharmaceutical market's R&D and production investment was about RMB 562 billion in 2021, expected to grow to RMB 956.6 billion by 2026, reflecting a CAGR of 11.2%[37]. - The global pharmaceutical R&D and production outsourcing service market was valued at approximately $140.3 billion in 2021, anticipated to reach $247.7 billion by 2026, with a CAGR of 12%[37]. - The company aims to leverage its international operational experience to provide customized services and solutions in gene and cell therapy development[34]. Risk Management - The company faces potential risks, including a decline in demand for drug development services, which could lead to clients postponing project development or cutting research budgets, adversely affecting the company's performance and outlook[43]. - The company operates in a highly regulated environment, with strict legal and industry standards governing drug development and production, and must continuously meet regulatory requirements to avoid penalties or loss of operating qualifications[46]. - The company is committed to complying with increasingly stringent environmental regulations, which may increase compliance costs[47]. Corporate Governance - The company is committed to maintaining high standards of corporate governance to protect and enhance shareholder interests[49]. - The management team consists of experienced professionals, with over 30 years in the pharmaceutical industry, ensuring effective leadership and strategic direction for the company[35]. - The audit committee has reviewed the interim financial information and confirmed compliance with applicable accounting principles and sufficient disclosure[51].

Financial Performance - In 2021, the company achieved revenue of RMB 7,443.8 million, a 45.0% increase compared to the previous year[8]. - The net profit attributable to shareholders was RMB 1,661.0 million, reflecting a growth of 41.7% year-on-year[8]. - The net cash flow from operating activities reached RMB 2,058.0 million, up 24.8% from the previous year[8]. - Total revenue for the year ended December 31, 2021, was approximately RMB 7,443.8 million, an increase of 45.0% compared to RMB 5,133.6 million for the year ended December 31, 2020[15]. - Gross profit for the year ended December 31, 2021, was approximately RMB 2,672.0 million, representing a 39.5% increase from RMB 1,916.1 million in 2020[15]. - Profit attributable to equity holders of the parent for the year ended December 31, 2021, was approximately RMB 1,661.0 million, up 41.7% from RMB 1,172.4 million in 2020[16]. - Net cash flow from operating activities for the year ended December 31, 2021, was approximately RMB 2,058.0 million, an increase of 24.8% compared to RMB 1,648.6 million in 2020[16]. - The company reported a diluted earnings per share of RMB 2.0537 for the year ended December 31, 2021, compared to RMB 1.4781 in 2020[17]. Asset and Equity Growth - By the end of 2021, total assets amounted to RMB 18,389.1 million, representing a 54.4% increase since the beginning of the year[8]. - The equity attributable to shareholders was RMB 10,129.2 million, which is a 14.2% increase from the start of the year[8]. - Total assets increased from RMB 4,143,664 thousand in 2017 to RMB 18,389,124 thousand in 2021, representing a growth of 343%[18]. - The equity attributable to the parent company grew from RMB 1,985,486 thousand in 2017 to RMB 10,129,241 thousand in 2021, marking a 410% increase[18]. - The leverage ratio improved significantly from 51.8% in 2017 to 44.0% in 2021, indicating a reduction in financial risk[18]. Client and Market Engagement - The company provided services to over 2,000 clients, including 800 new clients, and participated in 565 drug discovery projects in 2021[9]. - The company was involved in 77 domestic IND or NDA projects, with 56 projects submitted simultaneously in the US and other countries[9]. - In 2021, approximately 90% of the company's revenue came from a large, diverse, and loyal customer base, with 19.0% of revenue derived from the top 20 global pharmaceutical companies[29]. - Revenue from North American customers accounted for 64.2%, European customers (including the UK) contributed 15.6%, Chinese customers represented 17.1%, and other regions made up 3.1% of total revenue[29]. - The company introduced over 800 new customers in 2021, leading to a decrease in revenue concentration from the top 20 customers from 41.1% in 2020 to 33.8% in 2021[29]. Strategic Acquisitions and Expansion - The company expanded its international operations, acquiring Absorption Systems and Allergan Biologics Limited to enhance its capabilities in CGT services[11]. - The recent acquisition of a small molecule API commercialization facility in Cramlington, UK, aims to create a full industry chain service in chemical and production[11]. - The company plans to expand laboratory space in the UK and the US to meet growing business demands, including new laboratories in Boston and expansions in San Diego and Exton[12]. - The company completed the acquisition of Aesica Pharmaceuticals Limited for approximately GBP 55 million (about RMB 47.3 million), enhancing its small molecule CDMO service platform[40]. - The company acquired 100% equity in Zhongke Lingrui (Zhanjiang) Biotechnology Co., Ltd. for RMB 205.7 million, which has become a wholly-owned subsidiary[39]. Research and Development Focus - The company is focused on enhancing its capabilities in large molecule drugs and cell and gene therapy, aiming to become a global leader in multi-therapy drug development services[23]. - The company plans to launch a new CDMO platform for large molecule drug development and production, with an expected capacity of 70,000 square meters to be operational in 2023[27]. - The company is expanding its clinical research services, integrating platforms for both domestic and international clinical trials[27]. - The company is enhancing its capabilities in gene therapy and cell therapy, including the development of various analytical methods for DNA and RNA[28]. - The company is committed to providing high-level R&D services to assist partners in successfully developing new drugs, contributing to life sciences[19]. Sustainability and ESG Initiatives - The company has set sustainable development goals for 2021-2025, improving its ESG rating from BB in 2020 to BBB in 2021[13]. - The management team emphasized a focus on sustainability initiatives, aiming for a 15% reduction in carbon emissions by 2025[46]. - The company emphasizes environmental protection, health, safety, and intellectual property rights, ensuring robust protection for client IP, which has garnered widespread recognition and trust[51]. Corporate Governance and Management - The board proposed a final cash dividend of RMB 4.5 per share for the year ended December 31, 2021, totaling approximately RMB 357.4 million[16]. - The board of directors is committed to maintaining high levels of corporate governance, which is crucial for the group's development and safeguarding shareholder interests[85]. - The company has adhered to the corporate governance code during the relevant period from January 1, 2021, to December 31, 2021[85]. - The board consists of 11 members, including 9 males and 2 females, with diverse educational backgrounds and skills in various fields such as chemistry, business management, and law[87]. - The company emphasizes the importance of board diversity, considering factors like gender, age, and professional experience in its appointments[86]. Risk Management and Compliance - The company has established a risk management system aimed at improving risk prevention capabilities and promoting sustainable development[111]. - The internal audit system is designed to enhance the quality and efficiency of internal audits and improve the company's supervision and risk control mechanisms[111]. - The company has implemented a tiered management approach for comprehensive risk management, involving the board of directors, audit committee, and various functional departments[112]. - The company has conducted eight meetings of the supervisory board as of the report date[108]. - The company has established early warning and emergency response mechanisms to manage major risks and unexpected events[111]. Future Outlook and Guidance - The company provided guidance for the next fiscal year, projecting revenue growth of 20% to 1.44 billion[46]. - The company plans to increase its workforce by 10% to support growth initiatives[46]. - The company aims to enhance shareholder value through a share buyback program, allocating 50 million for this initiative in 2022[73]. - The company plans to implement strategic market strategies tailored to the characteristics of the Chinese market to accumulate customer resources and enhance competitiveness[57]. - The company recognizes the risk of a potential decline in demand for drug development services, which could adversely affect operational performance if the global pharmaceutical market growth slows[58].

Financial Performance - The company's revenue for Q1 2022 was CNY 2,102,899,933.93, representing a 41.19% increase compared to CNY 1,489,385,309.64 in the same period last year[4]. - Net profit attributable to shareholders was CNY 249,086,573.60, a slight increase of 1.31% from CNY 245,874,010.35 year-on-year[4]. - The net profit excluding non-recurring gains and losses was CNY 310,563,849.47, reflecting a 30.83% increase from CNY 237,376,010.22 in the previous year[4]. - Operating revenue for the reporting period reached ¥2,102,899,933.93, an increase of 41.19% compared to ¥1,489,385,309.64 in the same period last year[9]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥310,563,849.47, reflecting a growth of 30.83% from ¥237,376,010.22 year-on-year[9]. - The company reported a total profit of $316.18 million, compared to $282.48 million in the previous period, marking an increase of 11.96%[34]. - The adjusted net profit attributable to the parent company for the first quarter of 2022 was RMB 364,396 thousand, a significant increase of 39.1% year-over-year[47]. Cash Flow and Assets - The company's cash flow from operating activities was CNY 417,792,056.81, down 16.27% from CNY 498,953,761.05 in the same quarter last year[4]. - The total assets at the end of the reporting period were CNY 18,660,920,785.51, a 1.48% increase from CNY 18,389,124,353.35 at the end of the previous year[4]. - The company has shown a strong increase in cash and cash equivalents, with current assets totaling CNY 7,646,204,942.02, down from CNY 8,643,502,127.97, indicating a decrease of about 11.5%[22]. - The company’s cash and cash equivalents were RMB 2,873,493 thousand as of March 31, 2022, down from RMB 3,526,577 thousand at the end of 2021, indicating a decrease of about 18.5%[43]. Expenses and Liabilities - The company's cash flow from financing activities is -$298.11 million, a decrease from $285.02 million in the previous period, indicating a decline of 204.73%[41]. - Operating costs increased by 44.77% to ¥1,407,271,726.88, aligning with the revenue growth[10]. - The company reported a significant rise in financial expenses, up 416.87% to ¥40,234,145.81, primarily due to increased interest expenses[11]. - Total liabilities increased to CNY 8,316,165,204.05 from CNY 8,093,817,609.58, reflecting a rise of approximately 2.8%[26]. Shareholder Information - The top ten shareholders hold a combined 66.77% of the company's shares, with the largest shareholder owning 18.68%[12]. - The top ten unrestricted shareholders hold a total of 448,000,000 shares, with Shenzhen Xinchongkang Investment Partnership holding the largest share of 148,335,300 shares[14]. - The company’s major shareholders include individuals with significant connections, such as Mr. Lou Xiaoqiang, who holds 100% of Ningbo Longtai Kang Investment Management Co., Ltd.[15]. Research and Development - Research and development expenses increased by 36.27% to ¥39,647,299.50 from ¥29,095,136.05 year-on-year, indicating a commitment to enhancing R&D capabilities[11]. - The company reported a net investment loss of CNY 7,402,982.10 from joint ventures and associates, compared to a loss of CNY 344,610.97 in the previous period[77]. Acquisitions and Integrations - The company completed the acquisition of Aesica Pharmaceuticals Limited for approximately £55 million (around RMB 47.34 million), enhancing its CDMO service capabilities[18]. - The integration of clinical research services through Kanglong Chemical (Chengdu) Clinical Research Service Co., Ltd. aims to optimize clinical R&D capabilities and improve service quality[19]. Government Support - The company received government subsidies amounting to CNY 9,391,153.38 during the reporting period[6].

Financial Performance - Total revenue for the six months ended June 30, 2021, was approximately RMB 3,285.5 million, an increase of 49.8% compared to RMB 2,193.2 million for the same period in 2020[7]. - Gross profit for the same period was RMB 1,189.7 million, reflecting a 49.8% increase from RMB 794.4 million in the previous year[7]. - Profit attributable to equity holders of the parent was approximately RMB 564.8 million, up 17.9% from RMB 479.0 million for the six months ended June 30, 2020[8]. - Adjusted net profit under non-IFRS was RMB 651.4 million, representing a 50.9% increase from RMB 431.6 million in the prior year[7]. - Net cash flow from operating activities was approximately RMB 845.1 million, an increase of 36.8% compared to RMB 617.9 million for the same period in 2020[8]. - The company did not declare any interim dividend for the six months ended June 30, 2021[8]. - The company achieved a revenue of RMB 3,285.5 million, representing a 49.8% increase compared to the same period last year[14]. - Gross profit reached RMB 1,189.7 million, with a gross margin of 36.2%[14]. - Net profit attributable to the parent company was RMB 564.8 million, an increase of 17.9% year-on-year[14]. - Adjusted net profit attributable to the parent company was RMB 651.4 million, reflecting a 50.9% year-on-year growth[14]. Business Expansion and Services - The company is focused on expanding its capabilities in large molecule and cell and gene therapy research services[9]. - The company aims to become a global leader in multi-therapy drug development services[9]. - The business model includes laboratory services, CMC (small molecule CDMO) services, clinical research services, and large molecule and cell and gene therapy services[9]. - The company has established an integrated research and development service platform covering the entire drug development process and commercialization phase[9]. - The company has expanded its service offerings to include CMC (small molecule CDMO) services and clinical research services to meet customer demands in drug development[10]. - The acquisition of Absorption Systems and Allergan Biologics Limited has enhanced the company's capabilities in large molecule drug and cell and gene therapy services[10]. - The company provides comprehensive drug safety evaluation services that comply with GLP regulations from FDA, NMPA, and OECD, facilitating clinical trial applications for global clients[10]. - The clinical research services include regulatory and compliance registration, medical affairs, clinical operations, data management, and pharmacovigilance, with a focus on both domestic and international markets[12]. - The company has established a fully integrated clinical development service platform, enabling simultaneous IND submissions in China, the US, and Europe[12]. - The CMC CDMO services cover various stages of drug development, including process development and small-scale production, supporting clinical trials from Phase I to Phase III[11]. - The company has a global presence with facilities in Tianjin, Shaoxing, Ningbo, and the UK, continuously enhancing production capacity to meet international quality standards[11]. - The company’s laboratory services include DMPK/ADME and bioanalysis, crucial for small molecule drug development[11]. - The integration of services and technological advancements has led to a rapid increase in revenue from clinical research services[12]. - The company is accelerating the construction of its macromolecule drug CDMO platform, with a new facility in Hangzhou Bay covering nearly 70,000 square meters[14]. - The CDMO services include a full range of processes for cell and gene therapy products, supported by a license from the UK MHRA[14]. - The company is expanding its collaboration with domestic and international pharmaceutical and biopharmaceutical R&D enterprises[14]. Workforce and Human Resources - The company has a total workforce of 12,776 employees as of June 30, 2021, with 11,400 in R&D, production technology, and clinical services, representing 89.2% of the total[15]. - The company’s laboratory services workforce increased by 565 to 6,122 employees as of June 30, 2021, to meet growing business demands[16]. - As of June 30, 2021, the company expanded its CMC (small molecule CDMO) service team to 2,160 employees, an increase of 226 employees compared to December 31, 2020[17]. - The company increased its clinical research service workforce to 2,848 employees as of June 30, 2021, an increase of 640 employees from December 31, 2020[17]. Financial Position and Investments - The company raised approximately RMB 3,776 million from the issuance of zero-coupon convertible bonds, which will be used to expand drug development and production capacity[16]. - The company reported a leverage ratio of 44.2% as of June 30, 2021, compared to 25.0% on December 31, 2020[23]. - The net book value of mortgaged properties, plants, and equipment was approximately RMB 419.6 million as of June 30, 2021, compared to RMB 405.6 million as of December 31, 2020[23]. - The company had no significant contingent liabilities as of June 30, 2021[23]. - The company has established strong partnerships with top pharmaceutical and biotech companies globally, enhancing its reputation in the pharmaceutical R&D service industry[23]. - The company’s core technology focuses on providing a comprehensive drug development platform, which includes integrated CRO+CDMO services[23]. - The company has established a comprehensive chemical technology platform that spans the entire drug development process, including drug discovery, development, and production services[24]. - The company operates 17 entities globally, including locations in China, the UK, and the US, enhancing customer communication and regulatory compliance[25]. - The company has strengthened its global DMPK/ADME service network through the acquisition of Absorption Systems, solidifying its leading position in integrated DMPK services[24]. Market Trends and Strategic Focus - The demand for pharmaceutical R&D services in China is strong, driven by the shift from generic drugs to innovative drugs, making it one of the fastest-growing markets globally[27]. - The company aims to leverage the strong growth momentum in China's pharmaceutical R&D industry to further solidify its market leadership[27]. - The trend of pharmaceutical companies opting for R&D outsourcing to reduce costs and enhance efficiency is becoming more prevalent[28]. - The global drug service market is projected to grow from $99.9 billion in 2020 to $149.8 billion by 2024, with a compound annual growth rate (CAGR) of 10.7%[29]. - The Chinese drug service market is expected to increase from $12 billion in 2020 to $32.7 billion by 2024, representing a growth rate that is double that of the global market[29]. - The company aims to enhance its integrated drug development service platform and expand capabilities in large molecule drugs and cell and gene therapies[30]. - The company aims to strengthen its leadership in small molecule R&D services and enhance its technology and global expansion efforts[31]. Corporate Governance and Compliance - The company has committed to maintaining high levels of corporate governance, which is deemed crucial for the group's development and shareholder interests[38]. - The company has adopted the standard code of conduct for securities trading as per the listing rules, ensuring all directors and supervisors complied during the reporting period[39]. - The audit committee has reviewed the interim financial information and confirmed compliance with applicable accounting principles and sufficient disclosure[40]. - The company is actively monitoring trends in applicable policies and regulations to ensure ongoing compliance[36]. - The company emphasizes the importance of service quality and customer satisfaction as key factors for business growth and client retention[37]. Shareholder Structure and Incentives - The company has a significant shareholder structure with multiple entities holding substantial stakes, including Shenzhen Xincheng Investment Partnership with 157,142,855 A shares[45]. - The total percentage of shares held by major shareholders indicates a concentrated ownership structure, with the top three shareholders holding over 60% of the total shares[43]. - The company has established a long-term incentive mechanism to attract and retain talent through the A-share incentive plan[58]. - The incentive plan aims to align the interests of shareholders and employees, promoting the company's long-term development strategy[58]. - The company has a total of 227 individuals who have been granted restricted A-shares under the incentive plan, including senior management and key technical personnel[58]. Acquisitions and Strategic Investments - The company completed the acquisition of Allergan Biologics Limited in Q2 2021 to enhance its global cell and gene therapy service capabilities[31]. - The company acquired a 55% stake in Enyuan Pharmaceutical Technology (Beijing) Co., Ltd. for RMB 55,000,000, enhancing its control over the subsidiary[67]. - The company acquired a 38.42% stake in Zhaoqing Chuangya Biotechnology Co., Ltd for RMB 68,620,000 and subsequently increased its registered capital by RMB 41,400,000, resulting in a controlling interest of 50.01%[135]. - The acquisition of Pharmaron Biologics (UK) Ltd was completed for a cash consideration of USD 154,458,000 (approximately RMB 998,912,000), with the identifiable net assets valued at RMB 365,885,000 and goodwill of RMB 633,027,000 recognized[132].

Financial Performance - The company achieved a revenue of RMB 5,133.6 million in 2020, representing a year-on-year growth of 36.6%[8] - Gross profit reached RMB 1,916.1 million, with a gross margin of 37.3%[8] - Net profit attributable to shareholders was RMB 1,172.4 million, an increase of 114.3% compared to the previous year[8] - Adjusted net profit attributable to the parent company was RMB 1,064.0 million, reflecting a growth of 93.8% year-on-year[8] - The net cash flow from operating activities was RMB 1,648.6 million, up 75.6% from the previous year[8] - Total revenue for the year ended December 31, 2020, was approximately RMB 5,133.6 million, an increase of 36.6% compared to RMB 3,757.2 million for the year ended December 31, 2019[13] - Gross profit for the year was RMB 1,916.1 million, representing a 43.9% increase from RMB 1,331.7 million in 2019[13] - Profit attributable to equity holders of the parent company was RMB 1,172.4 million, up 114.3% from RMB 547.2 million in the previous year[14] - Net cash flow from operating activities was RMB 1,648.6 million, an increase of 75.6% compared to RMB 938.6 million for the year ended December 31, 2019[14] Business Expansion and Client Acquisition - The company added 721 new clients in 2020, bringing the total to over 1,500 clients, including 20 of the world's top pharmaceutical companies[9] - The company continues to expand its business segments rapidly following its A+H listing[8] - The company aims to enhance its leadership in small molecule services and accelerate the construction of a large molecule service platform in 2021[12] - The company aims to expand its services to include clinical research and commercial production, enhancing its integrated drug development capabilities[21] - The company is focused on accelerating the development of large molecule drugs and CGT products to strengthen its service offerings[21] Acquisitions and Strategic Partnerships - The acquisition of Absorption Systems LLC in November 2020 strengthened the company's global service capabilities in drug development[10] - The acquisition of Absorption Systems in November 2020 has enhanced the company's capabilities in CGT (Cell and Gene Therapy) services, positioning it as a leading platform in this emerging field[24] - The company has established strong partnerships with collaborators in North America, Europe, Japan, and China[4] - The company completed the acquisition of Beijing Lianshida in June 2020, enhancing its integrated CRO+SMO service platform[35] - The company announced the acquisition of 100% equity in Allergan Biologics Limited for a cash consideration of $120 million, equivalent to approximately RMB 776,556,000, expected to be completed in the second quarter of 2021[63] Research and Development - The company focuses on integrated R&D services across various fields, including drug chemistry, pharmacology, and clinical research[4] - The company has established a comprehensive pharmaceutical R&D service platform with 16 factories across China, the US, and the UK, employing over 11,000 staff, including more than 9,800 R&D, production technology, and clinical service personnel[24] - The company has developed nearly 20 unconventional in vitro drug metabolism experiments in 2020, focusing on 3D cell models and physiologically-based pharmacokinetic models[31] - The company established a biocatalysis department in 2020, developing nearly 1,000 biocatalytic enzymes for various organic synthesis reactions[29] - The company is building a 3D cell micro-sphere and organoid screening platform to improve drug efficacy and safety assessments compared to traditional 2D cell analysis systems[30] Operational Efficiency and Infrastructure - The company expanded its laboratory space by 22,500 square meters in the Beijing area to enhance its service capabilities[10] - The company is constructing the second phase of the Hangzhou Bay Life Science Industry Park, which will add over 2,500 research personnel and further expand laboratory services and CMC (small molecule CDMO) capacity[29] - The company is advancing the construction of the Shaoxing factory, which will cover 81,000 square meters and increase chemical reactor capacity by 600 cubic meters, with 200 cubic meters expected to be operational in H2 2021[29] - The company has established advanced technology platforms including a gene-encoded compound library, chemical proteomics platform, in vivo imaging technology platform, and 3D cell micro-sphere and organoid screening platform to enhance drug discovery processes[47] Environmental, Social, and Governance (ESG) Initiatives - The company is committed to environmental protection, health, safety, and intellectual property protection, ensuring long-term success and client trust[49] - The company has established an Environment, Safety, and Health Department to ensure compliance with applicable environmental regulations[68] - The company emphasizes sustainable development and integrates ESG requirements into daily management practices[148] - The company has established a social responsibility management system, with a committee responsible for handling all social responsibility-related matters[149] - The company conducted 12 anti-corruption training sessions with a total of 1,863 participants, achieving a 100% pass rate in assessments[158] Corporate Governance - The board consists of 11 members, including 3 executive directors, 4 non-executive directors, and 4 independent non-executive directors, ensuring a diverse governance structure[64] - The company has established four specialized committees: Strategic Committee, Audit Committee, Nomination Committee, and Remuneration and Assessment Committee[85] - The board is responsible for formulating the annual financial budget and profit distribution plan[85] - The company has complied with the corporate governance code since January 1, 2020, ensuring adherence to applicable laws and regulations[85] - The company emphasizes the importance of training and continuous professional development for directors and senior management[85] Market Outlook and Growth Projections - The global CRO+CMO services market is projected to grow from $99.9 billion in 2020 to $149.8 billion by 2024, with a CAGR of 10.7%[50] - The Chinese CRO+CMO services market is expected to reach $12 billion in 2021 and grow to $32.7 billion by 2024, doubling the global market growth rate[50] - The company aims to leverage the rapid growth of the Chinese pharmaceutical R&D industry to strengthen its market leadership[50] - The company has outlined a positive outlook for the next fiscal year, projecting a revenue growth of 20%[80] - The company plans to optimize and upgrade its global operational information systems to ensure the security of customer information and intellectual property[53] Employee Development and Workforce - The company has over 11,000 employees and operates in China, the United States, and the United Kingdom[4] - The workforce expanded to 11,000 employees, with over 9,800 in R&D, production technology, and clinical services, accounting for 89% of total staff[28] - The company focuses on employee development and integrates individual career growth into its overall strategic development[49] - The company has a strong emphasis on competitive employee compensation and benefits, regularly reviewing its compensation policy based on individual performance[62] - The company promotes a green office culture, encouraging employees to participate in energy-saving initiatives and resource utilization[187]

Financial Performance - The company reported total revenue of approximately RMB 2,193.2 million for the six months ended June 30, 2020, representing an increase of 34.0% compared to RMB 1,636.5 million for the same period in 2019[8]. - Gross profit for the same period was RMB 794.4 million, reflecting a growth of 52.1% from RMB 522.4 million year-over-year[8]. - Profit attributable to equity holders of the parent reached RMB 479.0 million, a significant increase of 196.9% compared to RMB 161.3 million in the prior year[9]. - The net cash flow from operating activities was approximately RMB 617.9 million, up 144.9% from RMB 252.3 million for the same period in 2019[9]. - The company did not declare an interim dividend for the six months ended June 30, 2020[9]. - The company achieved total revenue of RMB 2,193.2 million in the first half of 2020, representing a 34.0% increase compared to the same period last year[14]. - The net profit attributable to the parent company was approximately RMB 479.0 million, a significant increase of 196.9% year-on-year[14]. - Other income and gains amounted to approximately RMB 202.8 million, an increase of about 853.8% compared to the same period last year[18]. - The profit attributable to the owners of the parent company for the reporting period was RMB 479.0 million, an increase of 196.9% compared to RMB 161.3 million for the six months ended June 30, 2019[21]. - The total comprehensive income for the period was RMB 436,214 thousand, compared to RMB 154,974 thousand in the prior year, marking an increase of approximately 181%[72]. Operational Expansion - The company is a leading integrated pharmaceutical R&D service platform, expanding its services to late-stage clinical development and commercialization[10]. - The company has established a comprehensive drug discovery service platform, including capabilities in small molecule compound design and large-scale synthesis[10]. - The service offerings have been expanded to include clinical research and CMC services, compliant with NMPA, FDA, and OECD GLP standards[10]. - The company aims to provide customized services throughout the entire drug development process for pharmaceutical and biotech companies[10]. - The workforce has grown to over 9,000 employees across China, the United States, and the United Kingdom, enhancing its service capabilities globally[6]. - The company expanded its R&D and production capacity, with a total of 8,052 R&D, production technology, and clinical service personnel as of June 30, 2020, an increase of 1,651 from December 31, 2019[13]. - The company introduced over 190 new clients during the reporting period, with over 90% of revenue coming from a large, diverse, and loyal customer base, including the top twenty global pharmaceutical companies[12]. - The company expanded its clinical research service scope and completed the acquisition of Lian Sida, a third-party site management organization, on June 30, 2020[160]. - The company is strategically expanding its clinical services and large molecule R&D services to enhance its integrated drug development service platform[14]. Research and Development - The company has established a strong team capable of delivering quality services and keeping pace with advancements in pharmaceutical R&D[39]. - The company has accumulated extensive experience in compound design, structure-activity relationships, and synthesis capabilities during the drug discovery phase, which accelerates the overall drug development process[27]. - The company provides a comprehensive DMPK/ADME service platform that is crucial for clients' late-stage drug development strategies[27]. - The company has developed a unique understanding of the scientific challenges in expanding compound production, enhancing efficiency for clients[27]. - The company has established a protein and metabolomics platform that plays a crucial role in new drug development, providing valuable information from target discovery to safety evaluation[28]. - The company is committed to investing substantial human and capital resources in developing new technologies and upgrading its service platform[45]. - The company plans to invest in innovative pharmaceutical research technologies, including high-yield organic reaction systems and advanced imaging techniques for drug safety evaluation[179]. - The company aims to accelerate the development of biopharmaceutical analysis and testing services during the early development phase and establish capabilities in biopharmaceutical development and manufacturing[181]. Market Position and Strategy - The company is well-positioned to benefit from the growing demand for outsourced pharmaceutical R&D services, particularly in the Chinese market[28]. - The global drug service market is projected to grow from $94.4 billion in 2019 to $147 billion by 2023, with a compound annual growth rate (CAGR) of 10.3%[32]. - The Chinese drug service market is expected to increase from $10.8 billion in 2019 to $29.9 billion by 2023, representing a growth rate that is double that of the global market[32]. - The company aims to enhance its integrated drug development service platform and strengthen its global presence in the second half of 2020[35]. - The company is leveraging the rapid growth of the biotech startup sector and the increasing R&D spending in the industry to solidify its market leadership position[28]. - The company is committed to expanding its downstream business capabilities, including late-stage clinical development and commercialization[25]. - The company aims to enhance its integrated drug development service platform and strengthen its global presence, focusing on collaboration across different disciplines in drug development[178]. Financial Management - Financial costs decreased by approximately 68.4% to RMB 13.4 million, primarily due to the repayment of interest-bearing bank and other borrowings[19]. - Income tax expenses increased by 118.8% to RMB 65.7 million, attributed to growth in pre-tax profits from business operations[20]. - The net cash flow used in investing activities was RMB 2,032.4 million, an increase of RMB 1,530.4 million or 304.8% compared to the six months ended June 30, 2019[22]. - The company reported a leverage ratio of 17.8% as of June 30, 2020, down from 21.1% as of December 31, 2019[22]. - The company had total current assets of approximately RMB 5,283.5 million as of June 30, 2020, compared to RMB 5,944.5 million as of December 31, 2019[22]. - The company’s administrative expenses were approximately RMB 303.5 million, an increase from RMB 241.5 million in the same period last year, primarily due to ongoing business expansion[18]. - The company’s diluted earnings per share for the period was RMB 0.6045, compared to RMB 0.2500 in the same period last year, indicating a significant increase[71]. Corporate Governance - The company has adopted a competitive compensation and benefits policy for employees, which is regularly reviewed based on individual performance[47]. - The board of directors is committed to maintaining high levels of corporate governance, which is deemed crucial for the group's development and shareholder interests[46]. - The audit committee confirmed compliance with applicable accounting principles and standards during the reporting period, ensuring financial integrity[190]. - The company has complied with the corporate governance code throughout the reporting period, ensuring transparency and accountability[46]. - The company has not engaged in any purchase, sale, or redemption of its listed securities during the reporting period, reflecting a conservative financial strategy[47]. Risks and Challenges - The company faces risks related to obtaining necessary licenses for drug development and production, which could halt operations if not secured[42]. - The company's revenue from overseas clients significantly exceeds that from domestic clients, exposing it to foreign exchange risks, particularly with the USD, GBP, and EUR[43]. - The global drug research and development service market is highly competitive, and the company aims to build an integrated service platform to enhance its competitiveness[44]. - The company recognizes the risk of potential declines in drug development service demand and plans to enhance its market competitiveness through integrated strategies[182].